Smartlab Europe

Production & Manufacturing

Sustainable Nutraceutical Ingredients Shaping the Future

The Shift Toward Sustainable Ingredients One of the most significant transformations in the nutraceutical sector is the shift toward eco-friendly and responsibly sourced ingredients. Marine-Based Nutraceuticals Marine-derived ingredients such as seaweed, algae, and bioactive compounds are gaining traction due to their high efficacy...

High-Purity Ingredients: The New Benchmark in Nutraceuticals

In today’s competitive nutraceutical market, quality is no longer optional—it is essential. Consumers, regulators, and healthcare professionals are increasingly demanding products that deliver consistent results backed by science. As a result, high-purity ingredients are emerging as the new benchmark...

Why Integrated CDMO Partnerships Replace Multi-Vendor Models

Key Takeaways: The multi-vendor model in biopharma CMC creates communication risk, timeline gaps, and regulatory complexity Integrated CDMO partnerships consolidate development and manufacturing under a single organization with end-to-end knowledge of the process Single-partner models improve technology transfer efficiency...

Neuland Laboratories Expands Peptide Manufacturing Capacity

Neuland Laboratories is preparing to launch a new commercial peptide manufacturing facility at its 17-acre Bonthapally manufacturing campus, with the first phase expected to become operational in the summer of this year. The project forms part of a broader...

Regulatory Roadmap Set for UK Space-Based Drug Manufacturing

The UK government and national regulators have introduced a coordinated regulatory roadmap aimed at enabling space-based drug manufacturing, marking a significant step toward commercialising drug production in microgravity environments. The initiative brings together the UK Space Agency, the Medicines...

Taiwan Launches $755M Pharma Resilience Plan to Boost Supply

Taiwan is preparing a four-year national pharmaceutical resilience preparedness program designed to strengthen its domestic drug supply, supported by a 24 billion new Taiwan dollar ($755 million) investment. The initiative is intended to reinforce the country’s ability to maintain...

Norgine Invests £23m to Expand Hengoed Pharma Facility in UK

Norgine has confirmed a £23 million ($31 million) investment in its manufacturing facility in Hengoed, Wales, increasing the total capital directed toward the site to more than £50 million ($67 million) since 2022. The move is intended to strengthen...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »